Skip to main content

Table 5 Univariate and multivariate analyses for early recurrence in those receiving endocrine therapy and chemotherapy (early vs no recurrence)

From: Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

  Early vs no recurrence in combined therapy group
  Univariate analysis p Value Multivariate analysis p Value
ALDH1, ≤1 %/>1 % 4.054 (1.797–10.080) <0.001 4.625 (1.881–12.474) <0.001
Age, ≤50/>50 years 0.612 (0.349–1.067) 0.083 0.623 (0.330–1.164) 0.138
Tumor size, ≤20/>20 mm 2.553 (1.336–5.036) 0.004 2.130 (1.018–4.601) 0.044
Nodal metastasis negative/positive 4.357 (2.430–7.979) <0.001 3.856 (2.026–7.519) <0.001
Progesterone receptor staining, <20 %/≥20 % 1.035 (0.593–1.807) 0.903 Not selected  
Ki-67 staining, <20 %/≥20 % 1.592 (0.858–2.983) 0.140 0.791 (0.377–1.634) 0.529
Tumor grade 1 or 2/3 2.625 (1.285–5.595) 0.007 2.098 (0.940–4.848) 0.070
  1. ALDH1 aldehyde dehydrogenase 1